Pheochromocytoma and Paraganglioma Syndromes

Short placeholder heading

Expert Care and Treatment for Neuroendocrine and Carcinoid Tumors

Our Neuroendocrine and Carcinoid Tumors Program includes specialists from gastroenterology, pathology, radiology, surgical oncology, surgery, medical oncology, radiation oncology, nursing, research, and more who improve the outcome for patients.

Your care team will collaborate to develop a comprehensive, personalized treatment plan that offers the most advanced therapies and an array of supportive resources. 

Neuroendocrine and Carcinoid Tumors Program

What Are Pheochromocytoma and Paraganglioma Syndromes?

Pheochromocytomas and paragangliomas are rare types of neuroendocrine tumors that are typically benign, or noncancerous. Pheochromocytomas and paragangliomas are caused by an abnormal growth in chromaffin cells. Chromaffin cells are a type of cell that makes neurohormones and releases the neurohormones into the blood. Neurohormones are chemicals that are made by nerve cells and used to send signals to other cells. While many pheochromocytomas and paragangliomas are benign, some can become cancerous (malignant). Early detection and treatment of the tumor is important for optimal results. The diseases can be diagnosed by blood and urine tests, imaging tests or genetic testing.

While pheochromocytoma and paraganglioma are often used interchangeably, paragangliomas that occur in the adrenal medulla are called pheochromocytomas, and those outside the adrenal gland are called paragangliomas.

How Pheochromocytomas and Paragangliomas Develop

Pheochromocytomas develop in the adrenal glands, which are located above each kidney in the back of the upper abdomen. When chromaffin cells form a tumor elsewhere in the body, they are called paragangliomas.

The adrenal glands create hormones called catecholamines which help control one's heart rate, blood pressure, blood sugar, and the way the body reacts to stress. Sometimes pheochromocytoma and paraganglioma syndromes release extra neurohormones, adrenaline (epinephrine) and noradrenaline (norepinephrine), into the blood and cause signs or symptoms of disease.

Symptoms of Pheochromocytomas and Paragangliomas

Symptoms of pheochromocytoma and paraganglioma syndromes include:

  • High blood pressure/hypertension (most common)
  • Headache
  • Heavy sweating for no reason (hyperhidrosis)
  • Strong, fast, or irregular heartbeat
  • Shakiness
  • Extreme paleness (pallor)

How We Treat Pheochromocytomas and Paragangliomas

Dana-Farber Brigham Cancer Center experts at our Neuroendocrine and Carcinoid Tumors Program, part of the Gastrointestinal Treatment Cancer Center, are studying pheochromocytoma and paraganglioma syndromes to better understand who is at high risk and determine the best treatment. The program's multidisciplinary approach to treatment often involves medical therapies, surgery and chemotherapy. Experts work together to create an individualized treatment plan for each patient.

Pheochromocytomas and paragangliomas are increasingly being recognized as part of a larger syndrome with a genetic basis. Patients and families also have access to our Center for Cancer Genetics and Prevention. Adrenal endocrinologists, adrenal geneticists, and genetic counselors provide patients with new genetic technologies that can identify their risk, or a family member's risk, for developing pheochromocytoma and paraganglioma syndromes.

Clinical Trials Questions?


Research and Clinical Trials for Pheochromocytomas and Paragangliomas

Dana-Farber Brigham Cancer Center includes some of the world's top researchers and clinicians in pheochromocytoma and paraganglioma syndromes. Staffed by medical, surgical, and radiation oncologists, we offer the latest treatments fueled by ongoing research and discovery including new clinical trials.

Featured Clinical Trial: Pheochromocytomas and Paragangliomas

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
Trial Number: NCT04394858
Principal Investigators: Kimberly Perez, MD, Jaydira Del Rivero, MD
Trial Description: This phase II trial studies how well the addition of olaparib to the usual treatment, temozolomide, works in treating patients with neuroendocrine cancer (pheochromocytoma or paraganglioma) that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable).

Pheochromocytoma and Paraganglioma Treatment Team


Experts in our Neuroendocrine and Carcinoid Tumors Program work together with Brigham and Women's Hospital specialists to create an individualized treatment plan that offers you the most effective, comprehensive care available for pheochromocytoma and paraganglioma syndromes.


Jennifer Chan, MD, MPH, Oncologist
Kimberly Perez, MD, Oncologist
Matthew Nehs, MD, Endocrine Surgeon (Brigham and Women's Hospital)
Huma Rana, MD, MPH, Medical Genetics and Clinical Director Cancer Genetics and Prevention

See the complete list of our gastrointestinal cancer specialists.

Contact Us

New Patients

To request an appointment, please call 877-442-3324 or 617-632-3476, or complete the online form.

After scheduling, one of our nurses will call you to answer your questions and help you prepare for the appointment.

Referring Physicians

To refer a patient, please call 877-441-3324 or complete the online referral form.

Mailing Address

Neuroendocrine and Carcinoid Tumors Program
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215